Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dutch biotechnology company Crucell has entered into a co-exclusive PER.C6 and Advac technology license agreement with Wyeth Pharmaceuticals.
Subscribe to our email newsletter
Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.
Crucell’s AdVac technology is a recombinant vector technology used to develop novel adenoviral-based products.The company’s PER.C6 technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.